Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Kymriah (tisagenlecleucel) is a prescription drug that’s used to treat certain types of leukemia and lymphoma. The drug is given as an intravenous (IV) infusion. Kymriah is usually given as a ...

Novartis’ Kymriah is to receive fast reviews in the US and EU for a new use in a form of aggressive non-Hodgkin lymphoma, in a move that brings it into direct competition with Gilead's rival.

LONDON, GREATER LONDON, UNITED KINGDOM, March 8, 2025 /EINPresswire / -- How Has the Kymriah Market Performed in Recent Years? The Kymriah market has experienced significant expansion in recent ...